|  |
| --- |
| **Organization Name and Address:**  (type all information) |
|  |
| **PGY2 Pediatric Residency Program ASHP 5 digit code:** |
| **Residency Program Director (RPD) (full name, title and credentials):** |
|  |
| **RPD BPS credential type(s), certification number(s), and expiration date(s):** |
|  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Hospital Designations and Services** | **Primary Verification** | **Alternative****Documentation** | **Notes** |
| Accredited PGY2 Pediatric Residency program | Program provides most recent accreditation letter indicating minimum of a 4 year accreditation. Four year to full cycle will be accepted. |  |  |
| Children’s Oncology Group (COG) Center\* | <https://www.childrensoncologygroup.org/index.php/locations/>  | None | **Cancer Therapy Evaluation Program (CTEP #)** |
| Pediatric Transplantation & Cellular Therapy Consortium (PTCTC)\* | <https://www.theptctc.org/full-membership-insitutions>  | Proximity to participating PTCTC hospital where PGY2 Pediatric Oncology PSP Resident can obtain required experience / skill |  |
| Number of new pediatric oncology patients per year at your institution |  |  | Minimum > 100 |
| Number of pediatric stem cell transplants per year at your institution |  |  | Minimum > 15 |
| Number of open COG studies |  |  | No current threshold |
| Number of open studies outside of COG specific to childhood cancer (institutional, industry, other consortia, etc.) |  |  | No current threshold |
| Nursing staff APHON certified (Association of Pediatric Hematology / Oncology Nurses) | Y/N |  | Standards for Peds Cancer Ctr\* |
| Immediate access to fully staffed, on-site PICU | Y/N |  | Standards for Peds Cancer Ctr |
| Ability to perform radiography, CT, MRI, US, radionuclide imaging, angiography | Y/N |  | Standards for Peds Cancer Ctr |
| Clinical laboratory capable of monitoring antibiotic and antineoplastic drug concentrations | Y/N |  | Standards for Peds Cancer Ctr |
| Blood bank capable of providing irradiated and leuko-depleted blood components | Y/N |  | Standards for Peds Cancer Ctr |

|  |
| --- |
| **Any additional narrative the organization wishes to provide:** |
|  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Required Services** | **Name, Credentials and Job Title of Primary Preceptor for Learning Experience** | **Coverage: hours per day/days per week** **(e.g. 8/5)** | **# of beds** | **Notes** |
| Inpatient Oncology |  |  |  |  |
| Outpatient Oncology |  |  |  |  |
| Stem Cell Transplant |  |  |  |  |
| Oncology Infusion Center |  |  |  |  |
| Oncology Investigational Drug Services |  |  |  |  |
| Other: |  |  |  |  |
| Other:­­­­­­­­­ |  |  |  |  |

PGY2 Residency Program Director (Print Name): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Signature and Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Director of Pharmacy (Print Name): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Signature and Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

|  |  |
| --- | --- |
| FOR ASHP USE |  |
| Date Received |  |
| ASO Reviewer Name |  |
| COC Reviewer Name |  |
|  |  |
| Approved/date |  |
| Denied/date |  |
|  |  |

|  |  |
| --- | --- |
| Reporting: | Date |
| Decision to Site |  |
| National Matching Services |  |
| PharmAcademic™ |  |
| ASO Office (place review in Content Manager) |  |
| COC meeting |  |

\*Additional Information:

**COG:** Hospitals that have experts in treating children with cancer are usually member institutions of the NCI-supported [Children’s Oncology Group (COG)](https://www.childrensoncologygroup.org/)[Exit Disclaimer](https://www.cancer.gov/policies/linking). COG is the world’s largest organization that conducts clinical research to improve the care and treatment of children with cancer. [NCI's Cancer Information Service](https://www.cancer.gov/contact) can help families find COG-affiliated hospitals.

**PTCTC**: The PTCTC (formerly known as the Pediatric Blood and Marrow Transplant Consortium, PBMTC) was founded in 1992 and is the largest clinical trials group focused exclusively on blood and marrow transplants for children and adolescents.

**American Academy of Pediatrics**: Policy Statement, Standards for Pediatric Cancer Centers *Pediatrics* 2014: 134:410-414 (this publication has been reaffirmed in 2022 AAP book).